Weight-loss meds are on the chopping block.
Budget buster. As GLP-1 use quadruples, employers are uneasy about footing the bill. Among large US employers, 67% currently cover the drugs, but one in 10 say they’ll end access in 2027.
Opt-out. Citing pharmacy costs up ~20% YoY, Cigna and PwC dropped employee coverage for weight management, while others changed eligibility. As oral therapies accelerate adoption, most non-covering companies say they’re unlikely to start.
Opt-in. Bank of America says it now spends $250M+ annually—roughly 13% of its healthcare budget—covering GLP-1 medications. Calling it “good investment,” CEO Brian Moynihan pointed to research showing employer-sponsored GLP-1s yield fewer sick days, lower turnover, and slower medical cost growth.
HR issue. As chronic conditions rise, GLP-1s are moving from cost burden to health and productivity investment. Changing the economics for employers, Lilly negotiates drugs directly, Virta Health guarantees costs, and Amazon One Medical launched an integrated ecosystem.
Punchline: As preventative thinking challenges reactionary healthcare, the conversation is shifting from “can employers afford GLP-1s?” to “can they afford not to?”
